Chengdu Medeson Pharmaceutical Biotechnology

Chengdu Medeson Pharmaceutical Biotechnology is a biopharmaceutical company based in China that specializes in the research, development, and production of recombinant protein and peptide drugs. The company focuses on therapeutic areas such as endocrinology, metabolic diseases, and orthopedics, utilizing its proprietary protein expression platforms. Its lead candidate, MDS-002, is a recombinant human parathyroid hormone (teriparatide) developed for the treatment of osteoporosis. Medeson operates integrated facilities for R&D and GMP-compliant manufacturing to support its pipeline of biosimilars and innovative biologics. The company aims to address significant unmet medical needs in the Chinese and international markets.